Fernanda Waechter
Fernanda Waechter
  • 44
  • 181 017
DMF section 3.2.S.7 - Stability
Our aim here is to know for how long the API can be stored in the temperature and humidity conditions it will be exposed to, using the packaging material that was described in the previous section, considering the climate of the country where it is manufactured, as well as the country where it will be used in the drug product formulation.
There are different climate zones in the world, and the most critical condition must be considered for the stability studies. Alternative conditions may be used, in case of a controlled transport chain.
There are various studies that must be performed to understand the API stability.
The first one is the forced degradation study, which may be presented here or as part of the analytical validations in section 3.2.S.4.3. One of the objectives of this study is to expose the API to stressing conditions, so that in a short period of time it is possible to identify which conditions lead to degradation of the API - and which conditions we want to avoid during its life cycle.
This study includes for exposure to light, heat, humidity, oxidation, and acidic and alkaline hydrolytic conditions.
In order to identify if an API is sensitive to light, the ICH Q1B guideline must be followed, which recommends a confirmatory testing for photostability, in which the API must be exposed to at least 1.2 million lux.hour and 200 watt.hour UV light. This study allows us to conclude whether the API is considered photosensitive or not.
Another study is the accelerated stability study, in which the stability of the API will be evaluated in 6 months in conditions a bit more extreme than the normal ones, and the long-term stability study, which must represent the actual conditions to which the API will be exposed throughout its shelf life.
The conditions in such studies depend on the climate zone - e.g. for Zone Ivb, the accelerated stability is done at 40 C and 75% R.H., while the long-term stability is done at 30 C and 75% R.H.
The packaging material where the API is stored during these studies must represent the commercial packaging which was described in section 3.2.S.6.
The API stored in these conditions is tested throughout the time to understand if it is still approved in the quality control specifications. It is not necessary to perform all the tests that are done to release the API, only those which may be impacted by the API degradation.
Besides, we need to be sure that the assay and impurities methods that are used in these studies are in fact considered stability-indicating. And here comes the second objective of the forced degradation study: demonstrating that this combination of methods for assay and impurities is capable of specifically separating and quantifying the API and all the expected degradation impurities.
This means that if the API degrades and there is an increase in formation of impurities, this behaviour must be shown by such methods. So we should not have coelution of the API with impurities, which would hide this degradation. A good resolution between peaks must be shown, as well as the peak purity for the chromatograms.
Our intention in a forced degradation study is to see formation of impurities, so that this can be evaluated, but not in an exaggerated way - we usually look for up to 10% degradation, to avoid secondary degradation products which would not be expected in the real life of the API.
Moreover, ICH Q1B also recommends a photolytic forced degradation, which in general is a more extreme condition than the confirmatory test, since its objective is to form impurities to demonstrate that the method is stability-indicating.
A common deficiency is that there is no degradation in the forced degradation study because the API was not stressed enough. For example the API was exposed to heat for only one day and a conclusion was drawn that the API was stable to heat. The recommendation to seek the formation of impurities in this case would be to continue the exposure for up to 7 or 10 days, so that the study can finally be ended in case there is really no degradation.
If the forced degradation study is okay demonstrating that the methods are stability-indicating, the long-term study associated with the accelerated one will allow the manufacturer to establish an expiry or retest date for the API.
These conclusions are presented in the first part of the stability section, which consists of the stability summary and conclusions.
After that, Post-approval Stability Protocol and Stability Commitment are presented. This is a study done after approval of the API, adding one batch per year in a long-term study.
Finally, the stability data subsection will be where all the results are presented for the studies we have discussed:
- The photostability study
- The forced degradation study
- The accelerated and long-term stability studies - even if they are in progress.
Music: www.bensound.com
Переглядів: 544

Відео

DMF seção 3.2.S.7 - Estabilidade
Переглядів 3753 місяці тому
O nosso objetivo aqui, é saber por quanto tempo o IFA poderá ser armazenado nas condições de temperatura e umidade às quais ele será submetido, utilizando a embalagem que foi descrita na seção anterior, considerando tanto o clima do país onde é fabricado, como de onde será utilizado na fabricação do medicamento. Existem diferentes zonas climáticas no mundo, e a condição mais crítica deve ser co...
DMF section 3.2.S.6 - Container closure system
Переглядів 2693 місяці тому
The DMF in CTD format consists of 7 sections. In this video we will talk about section 3.2.S.6, which is about the container closure system, that is, the packaging material which is used to store the API which was produced. This is a very simple section of the DMF, but it's connected to the next and last DMF section which is very important, related to the API stability. Here we will find out wh...
DMF seção 3.2.S.6 - Embalagem
Переглядів 2053 місяці тому
O DMF no formato CTD consiste em 7 seções. Nesse vídeo vamos falar da seção 3.2.S.6, que traz informações sobre a embalagem que é utilizada para acondicionar esse IFA que foi produzido. Essa é uma seção simples, mas que tem bastante relação com a próxima e última seção do DMF e que é muito importante, de estabilidade. Aqui nós vamos descobrir qual a embalagem primária, ou seja, aquela que fica ...
DMF section 3.2.S.5 - Reference standards
Переглядів 3853 місяці тому
The DMF in CTD format consists of 7 sections. In this video we will talk about section 3.2.S.5, which is about the reference standards and materials. Standards are used both for the quality control analysis and for the analytical validations which were described in the previous section. Within the validation reports, the batches of standards that were used must have been informed. Any batch of ...
DMF seção 3.2.S.5 - Padrões de referência
Переглядів 1533 місяці тому
O DMF no formato CTD consiste em 7 seções. Nesse vídeo vamos falar da seção 3.2.S.5, que trata dos padrões, os materiais e substâncias químicas de referência e de trabalho. Padrões são utilizados tanto para as análises de controle de qualidade de rotina, como para as validações analíticas que foram descritas na seção anterior. Dentro dos relatórios das validações, os lotes de padrões que foram ...
DMF section 3.2.S.4 - Control of drug substance
Переглядів 6424 місяці тому
The DMF in CTD format consists of 7 sections. In this video, we will talk about section 3.2.S.4, which will describe how the manufacturer performs the quality control of the API. This section is divided in 5 parts - specification, methods, validations, batch analysis, and justification of specification. The information needs to be coherent throughout these different subsections and also in line...
DMF seção 3.2.S.4 - Controle do IFA
Переглядів 2334 місяці тому
O DMF no formato CTD consiste em 7 seções. Nesse vídeo vamos falar da seção 3.2.S.4, que é onde estará descrito como o fabricante realiza o controle de qualidade desse IFA. Essa seção é dividida em 5 partes - especificação, métodos, validações, análise de lotes e a justificativa da especificação. Aqui, as informações tem que conversar entre si e com as seções do DMF anteriores. Ou seja, se no c...
DMF section 3.2.S.3 - Characterization
Переглядів 8104 місяці тому
Section 3.2.S.3 is divided in two parts, first, the elucidation of structure, and then one of the most important parts of the DMF, the impurities chapter. In the elucidation of structure, the manufacturer will present results of analyses which confirm the identity and structure of that API, such as an infrared spectrum, UV spectrum, NMR, mass spectrum and elemental analysis. Here we will also s...
DMF seção 3.2.S.3 - Caracterização
Переглядів 2944 місяці тому
A seção 3.2.S.3 é dividida em duas partes - a elucidação da estrutura, e logo depois uma das partes mais importantes do DMF, o capítulo de impurezas. Na elucidação da estrutura, o fabricante vai apresentar resultados de análises que confirmam a identidade e a estrutura daquele IFA, como o espectro de infravermelho, de ultravioleta, RMN, massas, e análise elementar. Aqui também vai constar uma d...
DMF section 3.2.S.2 - Manufacture
Переглядів 6045 місяців тому
The DMF in CTD format consists of 7 sections. In this video we will talk about section 3.2.S.2. This is where we will find information about the manufacture of the API, first about its manufacturer and the site where it is produced, and then about the manufacturing process. This section is divided in applicant part - which is shared with clients and regulatory agencies - and restricted part - w...
DMF seção 3.2.S.2 - Fabricação
Переглядів 3245 місяців тому
O DMF no formato CTD consiste em 7 seções. Nesse vídeo vamos falar da seção 3.2.S.2. É nessa seção que vamos encontrar as informações sobre a fabricação do IFA, tanto quanto ao fabricante e o local onde o IFA é fabricado, como o processo de fabricação em si. Essa seção é dividida em parte aberta - a qual é compartilhada com os clientes e agências reguladoras - e parte fechada - que em geral é c...
DMF section 3.2.S.1 - General information
Переглядів 7495 місяців тому
In the previous video, we have shown that the DMF in a CTD format consists of 7 sections. In this video we will talk about the first one, section 3.2.S.1. This is a very simple section of the DMF, because it's usually informative and does not present many issues in terms of compliance with regulations. If you are evaluating this section, the assessment is simple and straightforward, especially ...
DMF seção 3.2.S.1 - Informações gerais
Переглядів 3045 місяців тому
English version here: ua-cam.com/video/bjHlG1RnCaw/v-deo.html Como vimos no vídeo anterior, o DMF no formato CTD consiste em 7 seções. Nesse vídeo vamos falar da primeira delas, a seção 3.2.S.1. Essa é uma das seções mais simples de um DMF, porque geralmente é mais informativa e sem grandes problemas de atendimento às legislações. Para quem estiver avaliando essa seção, a análise aqui é mais si...
How is the management of DMFs done by API and drug product manufacturers
Переглядів 7466 місяців тому
When the API manufacturer sells its API to a certain client, he also needs to present the quality documentation for that API, the DMF. To know more about DMFs, watch ua-cam.com/video/qpBk26yJQ3I/v-deo.htmlsi=sSMRHx-KqWbWviit The DMF is also a regulatory document, so it must be shared with the regulatory agency so that it approves the API for it to be produced and commercialized. This communicat...
Como é feito o gerenciamento de DMFs pelo fabricante do IFA e do medicamento
Переглядів 4786 місяців тому
Como é feito o gerenciamento de DMFs pelo fabricante do IFA e do medicamento
What is a DMF (drug master file)?
Переглядів 3,3 тис.6 місяців тому
What is a DMF (drug master file)?
O que é um DMF (drug master file)?
Переглядів 1,4 тис.6 місяців тому
O que é um DMF (drug master file)?
How to replace animal testing for skin sensitization using defined approaches
Переглядів 39110 місяців тому
How to replace animal testing for skin sensitization using defined approaches
How to better predict human cancer risk and reduce unnecessary animal testing
Переглядів 56211 місяців тому
How to better predict human cancer risk and reduce unnecessary animal testing
Can less than lifetime be applied for nitrosamines?
Переглядів 2,8 тис.Рік тому
Can less than lifetime be applied for nitrosamines?
Calculating limits for carcinogens: AI, PDE, and less than lifetime as per ICH M7
Переглядів 7 тис.2 роки тому
Calculating limits for carcinogens: AI, PDE, and less than lifetime as per ICH M7
How to deal with complex nitrosamines?
Переглядів 3,4 тис.2 роки тому
How to deal with complex nitrosamines?
Why should I get a CADIFA?
Переглядів 3,6 тис.2 роки тому
Why should I get a CADIFA?
Estratégias de controle e fator de purga para impurezas mutagênicas e nitrosaminas - Webinar
Переглядів 2,2 тис.3 роки тому
Estratégias de controle e fator de purga para impurezas mutagênicas e nitrosaminas - Webinar
Como conseguir uma CADIFA?
Переглядів 2,8 тис.3 роки тому
Como conseguir uma CADIFA?
Understanding the DNA
Переглядів 6243 роки тому
Understanding the DNA
Entendendo o DNA
Переглядів 2,7 тис.3 роки тому
Entendendo o DNA
How can I get a CADIFA anyways?
Переглядів 3,5 тис.3 роки тому
How can I get a CADIFA anyways?
Você já ouviu falar do Novo Marco Regulatório de IFAs no Brasil?
Переглядів 4,5 тис.3 роки тому
Você já ouviu falar do Novo Marco Regulatório de IFAs no Brasil?

КОМЕНТАРІ

  • @poonamkamble2976
    @poonamkamble2976 4 дні тому

    Ma'am can you please make a detailed video on new requirements for the CEP content (CEP 2.0). Thank you 😊

  • @jkgupta3334
    @jkgupta3334 6 днів тому

    Please upload more vedios NDSRI

  • @01746187159
    @01746187159 13 днів тому

    Very informative and covered all information in a simplified way.

  • @surimummadi
    @surimummadi 15 днів тому

    Lovely presentation 😊

  • @bablujejurkar661
    @bablujejurkar661 18 днів тому

    Superb cover all point great !!!! thank for edudacting.....

  • @dr.balakrishnaaegurla5560
    @dr.balakrishnaaegurla5560 Місяць тому

    TQ Ma'm

  • @sivajivanjinathan
    @sivajivanjinathan Місяць тому

    Very useful information.. Need your contact number.. E mail id

  • @sivajivanjinathan
    @sivajivanjinathan Місяць тому

    Hi mamm h r u

  • @subbuchikkam8599
    @subbuchikkam8599 Місяць тому

    Good information

  • @krupa.b8153
    @krupa.b8153 Місяць тому

    Do we need to combine general nitrosamines and NDSRIs while setting specification limit ( considering most potent one) .please suggest

    • @FernandaWaechter
      @FernandaWaechter 27 днів тому

      @@krupa.b8153 Hi Krupa, yes - if more nitrosamines are actually present and need to be controlled in the specification, then you should have a limit for total nitrosamines which may consider the most potent one and NDSRIs should also be considered for this. Unless their mechanism of mutagenicity is different e.g. category 4 or 5 based on CPCA, in which case they fall outside the cohort of concern. In this case I would recommend to confirm with the health authority but I would expect that the NDSRI doesn’t need to be part of that sum for total nitrosamines.

  • @lilianecruz6274
    @lilianecruz6274 2 місяці тому

    Obrigada pela aula ❤

  • @anahappy962
    @anahappy962 2 місяці тому

    Show! Faz um vídeo sobre PGMP.

  • @anapaulapirescostatereza9402
    @anapaulapirescostatereza9402 2 місяці тому

    Bom dia Fernanda! Assisti a todos os seus vídeos do DMF, parabéns mesmo pelo conteúdo! IFA ainda é um assunto que não é tão explanado como é a Indústria Farmacêutica, obrigada por compartilhar seu conhecimento nesta plataforma, excelente! Você ganhou uma seguidora, que espera um dia fazer a diferença como hoje você está fazendo!👏

    • @FernandaWaechter
      @FernandaWaechter 2 місяці тому

      Ahh que alegria ler o teu feedback! Obrigadaa, muito feliz de saber que os vídeos foram úteis :)

  • @nileshbawane842
    @nileshbawane842 2 місяці тому

    Nice explained...

  • @nileshbawane842
    @nileshbawane842 2 місяці тому

    nicely explained

  • @nileshbawane842
    @nileshbawane842 2 місяці тому

    Good

  • @nileshbawane842
    @nileshbawane842 2 місяці тому

    Crystal clear explained everything.. great

  • @nileshbawane842
    @nileshbawane842 2 місяці тому

    Very informative one

  • @nileshbawane842
    @nileshbawane842 2 місяці тому

    Great Fernanada

  • @kavyasridhanekula9658
    @kavyasridhanekula9658 2 місяці тому

    extraordinary explanation, simple yet effective

  • @tusharganage9814
    @tusharganage9814 2 місяці тому

    Keep Going dear this help me Lot ❤😊

  • @Firoz-lm4sz
    @Firoz-lm4sz 2 місяці тому

    Good 👍 But you speak very fast In next video please I request you to speak slow for better understanding.

    • @FernandaWaechter
      @FernandaWaechter 2 місяці тому

      Hi dear, sorry that I have spoken a bit faster to avoid the video from getting even longer. If you want, you can choose a slower speed for the video on youtube itself, and most of what I narrate is also written in the video description. Let me know if there is anything you do not understand

    • @vasanthdola6768
      @vasanthdola6768 2 місяці тому

      ​@@FernandaWaechter can you explain about NCE minus one and para iv filing

  • @muhammadzende1818
    @muhammadzende1818 2 місяці тому

    simple & effective. thanks👍

  • @rashvankhan5319
    @rashvankhan5319 2 місяці тому

    Nice explanation madam

  • @pullareddykarnati251
    @pullareddykarnati251 3 місяці тому

    Hi is it required to include the Impurities which are used for cut off study/ absence study or single time analysis. For instance, Impurity J is carrying from starting materials which was shown the fate in N-1 / N-2 Stage and same by analysing three consecutive batches.The report submitted.. is impurity J COA and structural elucidation data need to be submitted? Kindly clarify… We performed SM and Intermediates method validations and same were included in DMF.. Are impurities in Starting materials, Intermediates COAs and Structural elucidation need to be submitted? Kindly clarify…

    • @FernandaWaechter
      @FernandaWaechter 3 місяці тому

      Hi, since these impurities standards were used for analytical validations even for more simple validations applied to carryover studies, the COA and structural elucidation need to be available, although the regulatory agency may not require them to be included in the DMF. Some consider this as part of GMP compliance and in such case the characterization could be kept in house and provided if requested. I advise you to contact the specific regulatory agency to get clarification on their preferred approach.

    • @pullareddykarnati251
      @pullareddykarnati251 3 місяці тому

      @@FernandaWaechter thank you very much for your swift reply.

  • @zahraddeennuhu8186
    @zahraddeennuhu8186 3 місяці тому

    Please what about types and Submission of DMF ?

    • @FernandaWaechter
      @FernandaWaechter 3 місяці тому

      In this video we have only talked about type II DMF - for the drug substance. Other types of DMF can be found here www.fda.gov/drugs/drug-master-files-dmfs/types-drug-master-files-dmfs

  • @zahraddeennuhu8186
    @zahraddeennuhu8186 3 місяці тому

    Wow ,very well explained.

  • @amitgupta-yr5pl
    @amitgupta-yr5pl 3 місяці тому

    Thanks for sharing information

  • @arunpawar6127
    @arunpawar6127 3 місяці тому

    Plz share information about updated ICHQ2R2

  • @ameyatambe8129
    @ameyatambe8129 3 місяці тому

    What does gti here mean?

  • @varshareddy-we3dv
    @varshareddy-we3dv 3 місяці тому

    Hi ....you are simply amazing

  • @Sunriserrs
    @Sunriserrs 3 місяці тому

    Nice content

  • @pullareddykarnati251
    @pullareddykarnati251 3 місяці тому

    Kindly upload in English.. waiting

    • @FernandaWaechter
      @FernandaWaechter 3 місяці тому

      Here it is: ua-cam.com/video/vK8VVYRPocQ/v-deo.html

  • @septiaanrml
    @septiaanrml 3 місяці тому

    Such a great vid, very well explained! And this is coming from someone who just recently entered regulatory affairs :)

  • @carollouren7135
    @carollouren7135 4 місяці тому

    Muito bom esse vídeo Fernanda. seria interessante se você fizesse um vídeo explicando um cromatograma. :)

  • @amitgupta-yr5pl
    @amitgupta-yr5pl 4 місяці тому

    Great fernanda ,thanks for sharing

  • @franciscomel0
    @franciscomel0 4 місяці тому

    Boaa

  • @satnamom4667
    @satnamom4667 4 місяці тому

    Beautifully explained and represented pictorially. I am a fan of yours dear Frenda🎉

  • @amitgupta-yr5pl
    @amitgupta-yr5pl 4 місяці тому

    Excellent explanation Fernanda

  • @amitgupta-yr5pl
    @amitgupta-yr5pl 4 місяці тому

    Nicely explained

  • @srinivasulubhavanasi2734
    @srinivasulubhavanasi2734 4 місяці тому

    Explanation is good.add more videos please

    • @FernandaWaechter
      @FernandaWaechter 4 місяці тому

      thank you! the English version is published every 2 weeks

  • @amitgupta-yr5pl
    @amitgupta-yr5pl 4 місяці тому

    Explained well Fernanda

  • @AshwaniKumar-xi5xq
    @AshwaniKumar-xi5xq 4 місяці тому

    Very informative as always

  • @bhushanborse917
    @bhushanborse917 4 місяці тому

    Hi Fernanda, I am waiting for english version, please do inform me

    • @FernandaWaechter
      @FernandaWaechter 4 місяці тому

      HI Bhushan, English version was published today, here it is ua-cam.com/video/bAHxEd2k-6E/v-deo.html

  • @TheLari2010ssa
    @TheLari2010ssa 4 місяці тому

    Explicar coisas complexas de uma forma simples é uma das mais belas virtudes dos peritos no assunto. Parabéns Fer!

  • @TheLari2010ssa
    @TheLari2010ssa 4 місяці тому

    Ah, esses vídeos são maravilhosos. Mais didáticos impossível. Parabéns Fer!

  • @sathishgandu2221
    @sathishgandu2221 5 місяців тому

    Madam your explanation is very good and we expect more videos from you.

  • @bhushanborse917
    @bhushanborse917 5 місяців тому

    Good information provided, plz share more valuable information video in future.

  • @bhushanborse917
    @bhushanborse917 5 місяців тому

    Hi Fernanda ,English version plz , I am waiting

    • @FernandaWaechter
      @FernandaWaechter 4 місяці тому

      English version here: ua-cam.com/video/378Px16Twy8/v-deo.html

  • @bhushanborse917
    @bhushanborse917 5 місяців тому

    Fernanda you are providing valuable information, the way you make video, it gives clear idea about the concept